CARM - Carisma Therapeutics Inc.

https://www.carismatx.com

Momentum: Bearish

Recent News

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Carisma Therapeutics Inc. ( NASDAQ: CARM )

Benzinga • 2 months, 2 weeks ago • score: 0.15

NEW YORK, June 30, 2025 ( GLOBE NEWSWIRE ) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC ( the "M&A Class Action Firm" ) , has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. The company is headquartered in Philadelphia, Pennsylvania.

52W High

$1.27

52W Low

$0.14

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

3.69

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.06

EV/Revenue (<3 favorable)

1.53

P/S (TTM) (<3 favorable)

1.56

P/B (<3 favorable)

114.10

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

27.76%

Institutions (25–75% balanced)

19.81%

Shares Outstanding

41,788,100

Float

34,654,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

10,767,000

Gross Profit (TTM)

-27,717,000

EPS (TTM)

-1.19

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-4.10%

ROE (TTM) (>15% strong)

-3.63%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.10

Momentum

Bearish momentum

Value

0.0296

0.0301

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025